{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T07:51:12Z","timestamp":1761897072788},"reference-count":29,"publisher":"Bentham Science Publishers Ltd.","issue":"4","content-domain":{"domain":["eurekaselect.com"],"crossmark-restriction":true},"short-container-title":["CRR"],"published-print":{"date-parts":[[2019,11,25]]},"abstract":"<jats:sec>\n<jats:title>Background:<\/jats:title>\n<jats:p>Many patients may have resistance to TNF-blockers. These drugs may induce\nneutralizing antibodies. The determination of the drug levels of TNF-blockers and Anti-Drug\nAntibodies (ADAs) against TNF-blockers may help to make clinical decisions.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Objectives:<\/jats:title>\n<jats:p>The objective of this study was to associate and predict the drug levels of TNFblockers\nand ADAs in relation to disease activity in patients with Spondyloarthritis (SpA) and\nRheumatoid Arthritis (RA).<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Methods:<\/jats:title>\n<jats:p>Cross-sectional study including patients fulfilling ASAS classification criteria for SpA\nand 2010 ACR-EULAR classification criteria for RA. These patients were treated with Adalimumab\n(ADA), Infliximab (IFX), and Etanercept (ETN). A bivariate analysis and the chi-square test\nwere performed to evaluate the association of ADAs and drug levels with activity measures for\nSpA and RA. Five regression models analyzing drug levels, ADAs and disease activity measures\nusing a multiple linear regression were performed in order to evaluate the prediction of ADAs and\ndrug levels in relation to disease activity.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Results:<\/jats:title>\n<jats:p> In SpA, IFX levels were associated with BASDAI (Bath Ankylosing Spondylitis Disease\nActivity Index) (p=0.034). In RA, total drug levels were associated with DAS28-ESR (28 joint\nDisease activity Score-erythrocyte sedimentation rate), (p=0.008), DAS28-CRP (p=0.042), CDAI\n(Clinical Disease Activity Index) (p=0.047) and SDAI (Simple Disease activity index), (p=0.017).\nADA levels had association with CDAI (p=0.002) and SDAI (p=0.002). IFX levels were associated\nwith a DAS28-ESR (p=0.044), DAS28-CRP (p=0.022) and SDAI (p=0.022). ADAs were associated\nin SpA with BASDAI (p=0.027). Drug levels and ADAs did not predict disease activity in\npatients with SpA or RA.<\/jats:p>\n<\/jats:sec>\n<jats:sec>\n<jats:title>Conclusions:<\/jats:title>\n<jats:p>ADAs and drug levels of anti-TNF are associated with disease activity measures in\npatients with SpA and RA. However, they cannot predict clinical activity in these conditions.<\/jats:p>\n<\/jats:sec>","DOI":"10.2174\/1573397115666190708113601","type":"journal-article","created":{"date-parts":[[2019,7,9]],"date-time":"2019-07-09T07:40:55Z","timestamp":1562658055000},"page":"329-335","update-policy":"http:\/\/dx.doi.org\/10.2174\/bsp_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Drug Levels and Antibodies Against TNF-blockers in Spondyloarthritis and Rheumatoid Arthritis are Associated with the Activity but they do Not Predict it"],"prefix":"10.2174","volume":"15","author":[{"given":"Erika Marcela","family":"Padilla-Mart\u00ednez","sequence":"first","affiliation":[{"name":"Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Consuelo","family":"Romero-Sanchez","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Grupo de Inmunolog\u00eda Clinica Aplicada, School of Medicine, Hospital Militar Central\/ Universidad Militar Nueva Granada, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Manuel","family":"Bello-Gualtero","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Grupo de Inmunolog\u00eda Clinica Aplicada, School of Medicine, Hospital Militar Central\/ Universidad Militar Nueva Granada, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana Maria","family":"Mesa-Betancourt","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilson","family":"Bautista-Molano","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Grupo de Inmunolog\u00eda Clinica Aplicada, School of Medicine, Hospital Militar Central\/ Universidad Militar Nueva Granada, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rafael","family":"Valle-O","sequence":"additional","affiliation":[{"name":"Department of Rheumatology and Immunology, Hospital Militar Central, Bogota, Colombia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"965","reference":[{"key":"ref=1","doi-asserted-by":"publisher","first-page":"2205","DOI":"10.1056\/NEJMra1004965","volume":"365","author":"McInnes I.B.","year":"2011","unstructured":"McInnes I.B.; Schett G.; The pathogenesis of rheumatoid arthritis. N Engl J Med 2011,365(23),2205-2219","journal-title":"N Engl J Med"},{"key":"ref=2","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1136\/ard.2009.108233","volume":"68","author":"Rudwaleit M.","year":"2009","unstructured":"Rudwaleit M.; van der Heijde D.; Landew\u00e9 R.; The development of assessment of spondyloarthritis international society classification criteria for axial spondyloarthritis (part II): validation and final selection. Ann Rheum Dis 2009,68(6),777-783","journal-title":"Ann Rheum Dis"},{"key":"ref=3","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.autrev.2012.10.021","volume":"12","author":"Atzeni F.","year":"2013","unstructured":"Atzeni F.; Talotta R.; Salaffi F.; Immunogenicity and autoimmunity during anti-TNF therapy. Autoimmun Rev 2013,12(7),703-708","journal-title":"Autoimmun Rev"},{"key":"ref=4","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.autrev.2017.04.002","volume":"16","author":"Pecoraro V.","year":"2017","unstructured":"Pecoraro V.; De Santis E.; Melegari A.; Trenti T.; The impact of immunogenicity of TNF\u03b1 inhibitors in autoimmune inflammatory disease. A systematic review and meta-analysis. Autoimmun Rev 2017,16(6),564-575","journal-title":"Autoimmun Rev"},{"key":"ref=5","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"Mok C.C.","year":"2013","unstructured":"Mok C.C.; van der Kleij D.; Wolbink G.J.; Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol 2013,32(10),1429-1435","journal-title":"Clin Rheumatol"},{"key":"ref=6","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1136\/annrheumdis-2012-202545","volume":"72","author":"Vincent F.B.","year":"2013","unstructured":"Vincent F.B.; Morand E.F.; Murphy K.; Mackay F.; Mariette X.; Marcelli C.; Antidrug antibodies (ADAb) to tumour necrosis factor (TNF)-specific neutralising agents in chronic inflammatory diseases: a real issue, a clinical perspective. Ann Rheum Dis 2013,72(2),165-178","journal-title":"Ann Rheum Dis"},{"key":"ref=7","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1097\/BOR.0b013e328329ed8b","volume":"21","author":"Wolbink G.J.","year":"2009","unstructured":"Wolbink G.J.; Aarden L.A.; Dijkmans B.A.; Dealing with immunogenicity of biologicals: assessment and clinical relevance. Curr Opin Rheumatol 2009,21(3),211-215","journal-title":"Curr Opin Rheumatol"},{"key":"ref=8","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1002\/art.1780310302","volume":"31","author":"Arnett F.C.","year":"1988","unstructured":"Arnett F.C.; Edworthy S.M.; Bloch D.A.; The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988,31(3),315-324","journal-title":"Arthritis Rheum"},{"key":"ref=9","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"Aletaha D.","year":"2010","unstructured":"Aletaha D.; Neogi T.; Silman A.J.; 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010,62(9),2569-2581","journal-title":"Arthritis Rheum"},{"key":"ref=10","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1136\/ard.2010.133645","volume":"70","author":"Rudwaleit M.","year":"2011","unstructured":"Rudwaleit M.; van der Heijde D.; Landew\u00e9 R.; The assessment of spondyloarthritis international society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. Ann Rheum Dis 2011,70(1),25-31","journal-title":"Ann Rheum Dis"},{"key":"ref=11","doi-asserted-by":"publisher","first-page":"244","DOI":"10.1093\/rheumatology\/keg072","volume":"42","author":"Smolen J.S.","year":"2003","unstructured":"Smolen J.S.; Breedveld F.C.; Schiff M.H.; A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003,42(2),244-257","journal-title":"Rheumatology (Oxford)"},{"key":"ref=12","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.berh.2007.02.004","volume":"21","author":"Aletaha D.","year":"2007","unstructured":"Aletaha D.; Smolen J.S.; The Simplified Disease Activity Index (SDAI) and Clinical Disease Activity Index (CDAI) to monitor patients in standard clinical care. Best Pract Res Clin Rheumatol 2007,21(4),663-675","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"ref=13","doi-asserted-by":"publisher","first-page":"S47","DOI":"10.1002\/acr.20575","volume":"63","author":"Zochling J.","year":"2011","unstructured":"Zochling J.; Measures of symptoms and disease status in ankylosing spondylitis: Ankylosing Spondylitis Disease Activity Score (ASDAS), Ankylosing Spondylitis Quality of Life Scale (ASQoL), Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI), Bath Ankylosing Spondylitis Global Score (BAS-G), Bath Ankylosing Spondylitis Metrology Index (BASMI), Dougados Functional Index (DFI), and Health Assessment Questionnaire for the Spondylarthropathies (HAQ-S). Arthritis Care Res (Hoboken) 2011,63(Suppl. 11),S47-S58","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=14","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1002\/acr.21641","volume":"64","author":"Singh J.A.","year":"2012","unstructured":"Singh J.A.; Furst D.E.; Bharat A.; 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012,64(5),625-639","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=15","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1136\/ard.2011.151027","volume":"70","author":"Braun J.","year":"2011","unstructured":"Braun J.; van den Berg R.; Baraliakos X.; 2010 update of the ASAS\/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis 2011,70(6),896-904","journal-title":"Ann Rheum Dis"},{"key":"ref=16","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.reuma.2012.05.012","volume":"9","author":"Espi\u00f1o-Lorenzo P.","year":"2013","unstructured":"Espi\u00f1o-Lorenzo P.; Manrique-Arija S.; Ure\u00f1a I.; Baseline comorbidities in patients with rheumatoid arthritis who have been prescribed biological therapy: a case control study. Reumatol Clin 2013,9(1),18-23","journal-title":"Reumatol Clin"},{"key":"ref=17","first-page":"148","volume":"22","author":"Machado-Alba J.E.","year":"2015","unstructured":"Machado-Alba J.E.; Ruiz A.; The epidemiology of rheumatoid arthritis in a cohort of Colombian patients. Rev Colomb Reumatol 2015,22,148-152","journal-title":"Rev Colomb Reumatol"},{"key":"ref=18","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1093\/rheumatology\/ker124","volume":"50","author":"Pascual-Salcedo D.","year":"2011","unstructured":"Pascual-Salcedo D.; Plasencia C.; Ramiro S.; Influence of immunogenicity on the efficacy of long-term treatment with infliximab in rheumatoid arthritis. Rheumatology (Oxford) 2011,50(8),1445-1452","journal-title":"Rheumatology (Oxford)"},{"key":"ref=19","doi-asserted-by":"publisher","first-page":"1460","DOI":"10.1001\/jama.2011.406","volume":"305","author":"Bartelds G.M.","year":"2011","unstructured":"Bartelds G.M.; Krieckaert C.L.; Nurmohamed M.T.; Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA 2011,305(14),1460-1468","journal-title":"JAMA"},{"key":"ref=20","doi-asserted-by":"publisher","first-page":"921","DOI":"10.1136\/ard.2006.065615","volume":"66","author":"Bartelds G.M.","year":"2007","unstructured":"Bartelds G.M.; Wijbrandts C.A.; Nurmohamed M.T.; Clinical response to adalimumab: relationship to anti-adalimumab antibodies and serum adalimumab concentrations in rheumatoid arthritis. Ann Rheum Dis 2007,66(7),921-926","journal-title":"Ann Rheum Dis"},{"key":"ref=21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1002\/art.20019","volume":"50","author":"Keystone E.C.","year":"2004","unstructured":"Keystone E.C.; Schiff M.H.; Kremer J.M.; Once-weekly administration of 50 mg etanercept in patients with active rheumatoid arthritis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2004,50(2),353-363","journal-title":"Arthritis Rheum"},{"key":"ref=22","first-page":"40","volume":"25","author":"Dore R.K.","year":"2007","unstructured":"Dore R.K.; Mathews S.; Schechtman J.; The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol 2007,25(1),40-46","journal-title":"Clin Exp Rheumatol"},{"key":"ref=23","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","volume":"71","author":"Jamnitski A.","year":"2012","unstructured":"Jamnitski A.; Krieckaert C.L.; Nurmohamed M.T.; Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 2012,71(1),88-91","journal-title":"Ann Rheum Dis"},{"key":"ref=24","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1002\/acr.21649","volume":"64","author":"Anderson J.","year":"2012","unstructured":"Anderson J.; Caplan L.; Yazdany J.; Rheumatoid arthritis disease activity measures: American College of Rheumatology recommendations for use in clinical practice. Arthritis Care Res (Hoboken) 2012,64(5),640-647","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"ref=25","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203893","volume":"74","author":"Chen D.Y.","year":"2015","unstructured":"Chen D.Y.; Chen Y.M.; Tsai W.C.; Significant associations of antidrug antibody levels with serum drug trough levels and therapeutic response of adalimumab and etanercept treatment in rheumatoid arthritis. Ann Rheum Dis 2015,74(3)","journal-title":"Ann Rheum Dis"},{"key":"ref=26","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.intimp.2014.04.006","volume":"21","author":"Jung S.M.","year":"2014","unstructured":"Jung S.M.; Kim H.S.; Kim H.R.; Immunogenicity of anti-tumour necrosis factor therapy in Korean patients with rheumatoid arthritis and ankylosing spondylitis. Int Immunopharmacol 2014,21(1),20-25","journal-title":"Int Immunopharmacol"},{"key":"ref=27","doi-asserted-by":"publisher","first-page":"R160","DOI":"10.1186\/ar4675","volume":"16","author":"Paramarta J.E.","year":"2014","unstructured":"Paramarta J.E.; Baeten D.L.; Adalimumab serum levels and antidrug antibodies towards adalimumab in peripheral spondyloarthritis: no association with clinical response to treatment or with disease relapse upon treatment discontinuation. Arthritis Res Ther 2014,16(4),R160","journal-title":"Arthritis Res Ther"},{"key":"ref=28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.4172\/2167-7921.1000162","volume":"4","author":"Deaconu C.","year":"2015","unstructured":"Deaconu C.; Opris D.; Mazilu D.; How useful is anti-TNF serum level and anti-drug antibodies detection in evaluating patients with spondyloarthritis. J Arthritis 2015,4,1-6","journal-title":"J Arthritis"},{"key":"ref=29","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","volume":"74","author":"Kneepkens E.L.","year":"2015","unstructured":"Kneepkens E.L.; Krieckaert C.L.; van der Kleij D.; Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 2015,74(10),1825-1829","journal-title":"Ann Rheum Dis"}],"container-title":["Current Rheumatology Reviews"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/eurekaselect.com\/article\/download\/173301","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,17]],"date-time":"2019-12-17T04:35:11Z","timestamp":1576557311000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.eurekaselect.com\/173301\/article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,25]]},"references-count":29,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,11,25]]}},"alternative-id":["LiveAll1"],"URL":"https:\/\/doi.org\/10.2174\/1573397115666190708113601","relation":{},"ISSN":["1573-3971"],"issn-type":[{"value":"1573-3971","type":"print"}],"subject":[],"published":{"date-parts":[[2019,11,25]]},"assertion":[{"value":"Peer Reviewed","order":0,"name":"review_status","label":"Review Status","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Single blind","order":1,"name":"review_process","label":"Review Process","group":{"name":"peer_review_details","label":"Peer Review Details"}},{"value":"Checked with iThenticate","order":0,"name":"screening_status","label":"Screening Status","group":{"name":"plagiarism_screening","label":"Plagiarism Screening"}},{"value":"2018-09-30","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-13","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-12-17","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-25","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}